Viloxazine moderate dose associated with good ADHD outcomes
Fuente:
Wiley Open Access
Guardado en:
| Autor principal: | |
|---|---|
| Formato: | Artículo Open Access |
| Publicado: |
Wiley
2024
|
| Materias: | |
| Acceso en línea: | |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| _version_ | 1867020531658653696 |
|---|---|
| author | Alison Knopf |
| author_facet | Alison Knopf Alison Knopf |
| collection | Wiley Open Access |
| contents | Viloxazine moderate dose associated with good ADHD outcomes Alison Knopf The Brown University Child & Adolescent Psychopharmacology Update Attention‐deficit hyperactivity disorder (ADHD) is treated by medications, most recently, by viloxazine (Qelbree). Researchers in China looked at clinical trials to try to determine the best dose. Viloxazine was associated with better outcomes than placebo, with a bell‐shaped response curve suggesting that doses greater than 400 mg or greater than 7 mg/kg might not be linked to greater efficacy. Ascent curves tapered off about weeks 4 to 6. The curve for only 100 mg/d declined more rapidly, while the curves for 200 mg/dl and 400 mg/dl declined more gradually. In terms of adverse effects, there was a higher risk of discontinuation with viloxazine compared to placebo. The discontinuation rates due to adverse effects was 4.15% in the viloxazine group. 10.1002/cpu30925 http://onlinelibrary.wiley.com/termsAndConditions#vor |
| doi_str_mv | 10.1002/cpu30925 |
| format | Artículo Open Access |
| id | wiley_oa_10_1002_cpu30925 |
| institution | Wiley Open Access |
| license_str_mv | http://onlinelibrary.wiley.com/termsAndConditions#vor |
| publishDate | 2024 |
| publisher | Wiley |
| record_format | wiley_oa |
| spellingShingle | Viloxazine moderate dose associated with good ADHD outcomes Alison Knopf The Brown University Child & Adolescent Psychopharmacology Update Viloxazine moderate dose associated with good ADHD outcomes Alison Knopf The Brown University Child & Adolescent Psychopharmacology Update Attention‐deficit hyperactivity disorder (ADHD) is treated by medications, most recently, by viloxazine (Qelbree). Researchers in China looked at clinical trials to try to determine the best dose. Viloxazine was associated with better outcomes than placebo, with a bell‐shaped response curve suggesting that doses greater than 400 mg or greater than 7 mg/kg might not be linked to greater efficacy. Ascent curves tapered off about weeks 4 to 6. The curve for only 100 mg/d declined more rapidly, while the curves for 200 mg/dl and 400 mg/dl declined more gradually. In terms of adverse effects, there was a higher risk of discontinuation with viloxazine compared to placebo. The discontinuation rates due to adverse effects was 4.15% in the viloxazine group. 10.1002/cpu30925 http://onlinelibrary.wiley.com/termsAndConditions#vor |
| title | Viloxazine moderate dose associated with good ADHD outcomes |
| topic | The Brown University Child & Adolescent Psychopharmacology Update |
| url | https://onlinelibrary.wiley.com/doi/10.1002/cpu30925 |